News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Philip Philip, MD

Articles by Philip Philip, MD

Phillip Phillip, MD

Dr Philip on Considerations for Selecting First-Line Treatment in Newly Diagnosed, Low-Risk GI NETs

ByPhilip Philip, MD

January 16th 2025

Philip Philip, MD, discusses considerations for selecting first-line treatment for newly diagnosed, low-risk gastrointestinal neuroendocrine tumors.

Latest Updated Articles

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma

2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes

HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts

Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC